Vaccine study for CLL patients to prevent pneumococcal infections
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or small lymphocytic lymphoma (SLL), confirmed by a specialist
- You are at least 18 years old
- You fit one of these groups: either you have never been treated for CLL, or you took venetoclax for at least 12 months
- You have not had a severe allergic reaction to a pneumococcal vaccine before
- You have not received PCV13 or PCV20 in the past 5 years (some PPSV23 timing may still allow participation)
- You do not have an active infection that requires antibiotics, and your medications fit the rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a specific plan for giving a pneumococcal vaccine in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help improve protection against pneumococcal infections in patients who have not started CLL/SLL treatment yet.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
This trial tests a combination of two drugs (nemtabrutinib and venetoclax) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have never received cancer treatment before. The goal is to see if this combination can shrink the cancer and help patients live longer.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.